November 12, 2026: Treat to Target: Optimizing Strategies for Remission and Mucosal Healing

November 12, 2026

Welcome to the third session of this ECHO program!


Claiming Credit 
Thank you for attending the session on November 12th, 2026. Once logged in, please click on "Take Course" on the right-hand side and your enrollment will be recorded. You will be prompted to claim your credit on the following page

Target Audience

This ECHO® series is designed for gastroenterologists, NPs, PAs, nurses, and pharmacists in community and academic GI practices. Teams and individual GI providers are welcome to attend!

Learning Objectives:
At the conclusion of this learning activity, participants will be better able to:

  1. Recognize advanced therapeutic options and exhibit a comprehensive understanding of the pharmacodynamics, efficacy, and safety profile of current and emerging IBD treatments, including biologics, and small molecule inhibitors.
  2. Accurately classify a patient's IBD phenotype, predict disease behavior, and identify clinical and diagnostic features relevant to creating an appropriate therapy plan.
  3. Tailor treatment to patient-specific presentation: select the most appropriate therapy based on IBD phenotype, behavior, severity, presence of complications, and patient preferences.
  4. Optimize treatment strategies employing a treat to target approach: modify treatment strategies based on the achievement of treatment targets including clinical response, biomarker response, clinical remission, endoscopic remission, and future targets of histologic/mucosal healing.
  5. Identify and mitigate the common barriers to medication access, including financial constraints, insurance coverage issues, and health system inefficiencies, particularly keeping in mind the needs of the underserved.
  6. Collaborate with each member of the interprofessional team to provide the best care possible for people with IBD.

Grantor Acknowledgement:

Supported by educational grants from AbbVie, Celltrion USA, Janssen Biotech, administered by Janssen Scientific Affairs LLC, and Takeda Pharmaceuticals U.S.A.,Inc.

Course summary
Available credit: 
  • 1.00 AAPA Category I CME
  • 1.00 ABIM Medical Knowledge
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 ANCC
  • 1.00 Participation
Course opens: 
11/12/2026
Course expires: 
11/12/2027
Event starts: 
11/12/2026 - 7:00pm EST
Event ends: 
11/12/2026 - 8:00pm EST
Add to calendar: 
Rating: 
0

Accreditation Statement
This activity is developed by Boston University Chobanian & Avedisian School of Medicine.

In support of improving patient care, Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

 

Physician Accreditation
Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Please note that 4.0 credits are based on participation in all four ECHO® sessions.
 

American Board of Internal Medicine Maintenance of Certification (MOC) Part 2 Credit

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


By participating and claiming credit, you agree to BU sharing your information with ACCME PARS the data conduit to the ABIM.
Please note that 4.0 credits are based on participation in all four ECHO® sessions.
 

Nurse Accreditation
Nursing Contact Hours: 4.0, of which XX are eligible for pharmacology credit.
Please note that 4.0 credits are based on participation in all four ECHO® sessions.
 

Physician Associate Accreditation

Boston University Chobanian & Avedisian School of Medicine has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 4.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Please note that 4.0 credits are based on participation in all four ECHO® sessions.

 

 

Questions: If you have any questions about the program, registering or claiming credit please write [email protected] and your questions will be answered. 

Available Credit

  • 1.00 AAPA Category I CME
  • 1.00 ABIM Medical Knowledge
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 ANCC
  • 1.00 Participation
Please login or register to take this course.